Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMN4LMT)

Drug Name

Oxeglitazar Drug Info

Synonyms

EMD-336340; EML-16156; EML-4156; LM-4156

Indication

Disease Entry	ICD 11	Status	REF
Gout	FA25	Phase 1	[1]

Cross-matching ID

Molecule(s) Related to This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Peroxisome proliferator-activated receptor alpha (PPARA)	TTJ584C	PPARA_HUMAN	Modulator	[1]
Peroxisome proliferator-activated receptor gamma (PPAR-gamma)	TTZMAO3	PPARG_HUMAN	Modulator	[1]

------------------------------------------------------------------------------------

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule	Molecule Type	Gene Name	Liver	Colon	Kidney	Small Intestine
Peroxisome proliferator-activated receptor gamma (PPAR-gamma)	DTT	PPARG	5.576	6.977	5.736	5.758
Peroxisome proliferator-activated receptor alpha (PPARA)	DTT	PPARA	4.65	4.138	4.564	5.031

Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease

Gout

ICD Disease Classification

FA25

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Peroxisome proliferator-activated receptor gamma (PPAR-gamma)	DTT	PPARG	2.41E-01	-0.06	-0.25

Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1	Therapeutic potential of aleglitazar, a new dual PPAR-alpha/gamma agonist: implications for cardiovascular disease in patients with diabetes mellitus. Am J Cardiovasc Drugs. 2010;10(4):209-16.